In-silico Prediction of Maximum Binding Affinity of Disease-Modifying Antirheumatic Drugs with Homo sapiens Acrosomal Protein SP-10
نویسندگان
چکیده
The increasing population has prompted scientists to explore novel technologies manage health concerns. Multidrug therapies occupy a prominent position in disease management. Among all the pharmaceuticals, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) captivated global researchers accomplish needs of Rheumatoid Arthritis (RA) Researchers have documented side effects associated with medications addition therapeutic effects. issue infertility is one
منابع مشابه
Disease-modifying Antirheumatic Drugs (DMARDs)
Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...
متن کاملDisease-modifying Antirheumatic Drugs (DMARDs)
Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...
متن کاملBiologic Disease-Modifying Antirheumatic Drugs
1. Distinguish between biologic DMARD use and nonbiologic DMARD use in the treatment of rheumatoid arthritis (RA). 2. Assess the differences between classes of biologic disease-modifying antirheumatic drug (DMARD) therapy. 3. Based on individual patient characteristics, construct a treatment and monitoring plan for a patient with RA and, when appropriate, include biologic DMARD therapy. 4. Just...
متن کاملDisease-modifying Antirheumatic Drugs (DMARDs)
Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...
متن کاملTreatment of ankylosing spondylitis with disease modifying antirheumatic drugs.
Ankylosing spondylitis (AS) is a common (prevalence 0.2-0.9%) chronic inflammatory disease that mainly affects young males and is characterised by inflammatory back pain with sacroiliitis and often arthritis of the peripheral joints. The disease can lead to deformities of the vertebral column, joints and extra-spinal structures, e.g. the eye (uveitis). Non-steroidal anti-inflammatory drugs (NSA...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International journal of pharmaceutical research and allied sciences
سال: 2023
ISSN: ['2277-3657']
DOI: https://doi.org/10.51847/ptup5schcd